This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Progenics Pharmaceuticals Announces A Changing Of The Guard On Its Board Of Directors

-Michael Kishbauch, former CEO of Achillion, joins Board

-Stephen Goff retires from Board following 20 years of service

TARRYTOWN, N.Y., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) has announced that Michael D. Kishbauch, an experienced and innovative leader in the healthcare industry, has been elected to its Board of Directors. Stephen P. Goff, Ph.D., who has served on the Board since 1993, has retired. Both are effective today. Mr. Kishbauch has held senior management positions in the life sciences industry for over 28 years, most recently as President and CEO of Achillion Pharmaceuticals.

"Our newest Board member brings a wealth of experience, expertise and enthusiasm to our team," said Peter Crowley, Chairman of the Board of Progenics.

"The Board at Progenics is instrumental in providing the vision and support needed to further our mission to become a pre-eminent oncology company. We are honored to welcome Michael to our Board as we work to address the unmet medical needs of cancer patients and their families," said Mark R. Baker, Chief Executive Officer.

Mr. Kishbauch has extensive operational, strategic, product planning, promotion, sales, marketing and product launch experience. Prior to his work at Achillion, Michael founded and served as President and Chief Executive Officer of OraPharma, Inc., which was a publicly traded, commercial-stage pharmaceutical company focused on oral health care. OraPharma was acquired by Johnson & Johnson. Michael previously held senior management positions with MedImmune, Inc.; has held board positions with several other life sciences companies; and continues to serve on Achillion's Board. He holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University.

"I am pleased for the opportunity to help guide Progenics, and grateful to play a role in fundamentally changing the landscape for patients suffering from prostate and other cancers," said Mr. Kishbauch. "My experience in the healthcare sector helps me to appreciate the value an organization like Progenics brings in advancing innovative, yet practical, approaches to diagnosing and treating prostate and other cancers."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs